{"id":1115,"date":"2003-12-01T12:02:00","date_gmt":"2003-12-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/herzinsuffizienz-auch-nach-etanercept"},"modified":"2003-12-01T12:02:00","modified_gmt":"2003-12-01T11:02:00","slug":"herzinsuffizienz-auch-nach-etanercept","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/herzinsuffizienz-auch-nach-etanercept","title":{"rendered":"Herzinsuffizienz auch nach Etanercept"},"content":{"rendered":"<p>Antagonisten des Tumor-Nekrose-Faktors alpha (TNF alpha; Infliximab = Remicade, Etanercept = Enbrel) werden z.B. &#8211; in verzweifelten F\u00e4llen &#8211; zur Behandlung der chronischen Polyarthritis und von Fisteln bei M. Crohn angewendet. Wir haben \u00fcber Wirkungen und unerw\u00fcnschte Wirkungen (UAW) berichtet (1, 2). Die dramatischste Komplikation ist die Reaktivierung einer Tuberkulose, auch mit t\u00f6dlichem Verlauf. In [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antagonisten des Tumor-Nekrose-Faktors alpha (TNF alpha; Infliximab = Remicade, Etanercept = Enbrel) werden z.B. &#8211; in verzweifelten F\u00e4llen &#8211; zur Behandlung der chronischen Polyarthritis und von Fisteln bei M. Crohn angewendet. Wir haben \u00fcber Wirkungen und unerw\u00fcnschte Wirkungen (UAW) berichtet (1, 2). Die dramatischste Komplikation ist die Reaktivierung einer Tuberkulose, auch mit t\u00f6dlichem Verlauf. In [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1891,180,1263,1262,1257,1260,1261,1259,1258,1264],"class_list":["post-1115","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-etanercept","tag-herzinsuffizienz","tag-tnf-alpha-antagonisten","tag-tnf-alpha-antikoerper","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-antikoerper","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1115"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1115\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}